The Best Hemp Delta-9 Gummies –

Before we get into the best delta-9 hemp gummies, let’s understand what we mean by “hemp.”

You might be wondering what the difference is between cannabis and hemp. It might surprise you that these two plants have little to no physical differences. The only difference is their psychoactive components.

Hemp is simply a term used for cannabis plants that contain 0.3% delta-9 THC or less by dry weight. Cannabis, on the other hand, contains all those precious cannabinoids, terpenes, and phytocannabinoids used for recreational or medicinal purposes.

So, when we say hemp gummies, we mean federally legal cannabis gummies. Read on for more information about where to find the best delta-9 hemp gummies that pack a potent punch.

Cannabis Reg. Update: Cannabis Taxes, Workplace Discrimination, Sales Launch In Vermont, NM Expungement – – Benzinga

Cannabis Taxes & Tax Revenue in CO and WA: A New Report

The Tax Policy Center reported that due to the lack of a standard cannabis tax in the US, governments use three different types of cannabis taxes, based on a percentage-of-price tax, a weight-based tax and a potency-based tax.

Image by the Tax Policy Center

The report showed that in Fiscal Year 2022, Colorado “collected $353.7 million in

Moreover, researchers also detailed „each state’s cannabis tax system, provides data on cannabis tax revenue, explains the pros and cons of different cannabis taxes, and discusses the various goals of those taxes.”

Workplace Discrimination: Buffalo Firefighter Wants His Job Back

A 38-year-old firefighter, who served in the Air Force in Iraq and Afghanistan, was fired from his job because he tested positive for marijuana though he is a certified medical marijuana patient who uses cannabis to treat PTSD and back pain.

Scott Martin, a 12-year veteran with the Buffalo Fire Department said that doctors prescribed him, „to treat his back pain, OxyContin and later shots of Tramadol” into his lower spine. „Imagine getting an epidural every three or four months,” he said. „I don’t get the injections anymore because of the medical marijuana. I’m not on any opiates anymore.” Thus, he proceeded with his legal action to get his job back.

Recently, State Supreme Court Judge Catherine Nugent Panepinto ruled that Martin can continue legal action to get his job back. However, Panepinto refused to reinstate him as requested. The judge said she will continue to review each side’s arguments before making a decision on whether he can return to duty.

Under thestate’s Compassionate Care Act, „conditions that can be treated with cannabis should be considered disabilities, so firing him should be considered workplace discrimination,” said David Holland, Martin’s attorney.

Vermont Recreational Cannabis Sales Will Launch Soon

On Sep. 14, the Vermont Cannabis Control Board (CCB) issued adult-use retail licenses to Mountain Girl Cannabis in Rutland, FLORA Cannabis in Middlebury, and CeresMED in Burlington, formerly Champlain Valley Dispensary; which permits that at least these three Vermont stores will have adult-use cannabis sales beginning on Oct. 1.

“There’s nothing specifically saying that businesses must wait until Oct. 1 to begin sales, if they’re licensed,” Nellie Marvel, outreach and education manager for the CCB said. “They may opt to do so, as that’s the date everyone is familiar with, but they do not necessarily have to. Others may opt to wait until the supply chain becomes more established—this is a decision every business owner will have to make for themselves.”

According to a news release from SLANG Worldwide SLNG SLGWF, the company’s subsidiary CeresMED will launch recreational marijuana sales at its 190 College Street location on Oct. 1, reported the Green Report Market.

Vermont is the 15th U.S. state marijuana market that SLANG has entered so far, according to the release.

Other stores plan on launching as soon as they can get their affairs in order, the Burlington Free Press reported.

“It’s also important to underscore that these first licensed retailers don’t represent the end of the road in the journey towards a more sensible regulated cannabis market in Vermont,” Marvel added.

“Delays in licensing at the beginning of the process, especially for our outdoor cultivators, means that not everyone was able to participate in the market fully this year,” Marvel concluded. “This also means we’re likely to see early supply shortages, which has happened in the initial rollout of each adult-use state as the supply chain continues to develop.”

New Mexico: Courts Seek To Alter Cannabis Expungement

Recently, the Chief Justice of New Mexico’s Supreme Court said that the state’s judicial branch „will seek changes during the upcoming 60-day legislative session to a 2021 law that mandates small-level cannabis convictions be expunged from criminal records.”

Shannon Bacon, Supreme Court Chief Justice said when lawmakers legalized adult-use marijuana sales, it „placed a heavy burden on judicial staffers who have had to sift through voluminous criminal records to determine which convictions qualify to be purged. Instead of putting the onus on the judicial branch to identify and expunge cannabis-related convictions, it should be up to affected individuals to file applications for such action,” Bacon said during a meeting of the legislative Courts, Corrections and Justice Committee.

“We think there’s a more straightforward and simplistic way to handle this that will take what has been an incredibly onerous process off the judiciary and put the control in the hands of the person that’s had the conviction.”

Under the expungement law, criminal convictions for trafficking or possession of large amounts of marijuana – more than 2 ounces – are not eligible to be expunged since purchase and public possession of such an amount of cannabis remains illegal under the state’s cannabis legalization law, reported the Albuquerque Journal.

In addition, Barry Massey, spokesperson for the state Administrative Office of the Courts, said „there is no data available yet as to exactly how many New Mexico residents have had their past cannabis-related convictions expunged since the law took effect (…) There was no data as to the number of objections filed by prosecutors in advance of a July 1 deadline.” 

Image by Benzinga

Legal cannabis sales begin this weekend in Vermont – WAMC

Legal cannabis sales for adults 21 and older begin Saturday in Vermont.

The first licenses for adult-use retail cannabis sales were issued on September 14th by the Vermont Cannabis Control Board to Mountain Girl Cannabis in Rutland and Flora Cannabis in Middlebury. Ceres Med in South Burlington will transition from medical to adult-use cannabis sales. A fourth has been licensed but is not yet ready to open.

Adults over 21 must present a valid ID and can purchase up to one ounce of marijuana.

Vermont’s Cannabis Control Board prioritized review and waived licensing fees for social equity applicants. Such applicants are Black or Hispanic, or from communities that historically have been or had a family member who has been incarcerated for a cannabis-related offense.

The Associated Press contributed to this report. Contents © copyright 2022. All rights reserved.

New York’s Medical Cannabis Patients and Caregivers may Grow Cannabis at Home – JD Supra

Effective October 5, New York medical cannabis patients age 21 and older may grow up to three mature and three immature cannabis plants under new rules adopted by the state’s Cannabis Control Board.

Designated caregivers who care for those under age 21 or those unable to cultivate their own cannabis will be permitted to grow up to six mature (buds showing) or immature plants. Caregivers are permitted to grow for up to four patients.

Only certified patients and designated caregivers registered with the Office of Cannabis Management are able to engage in home grow, and they are not permitted to sell the cannabis they grow.

The cannabis must be grown in a secure location within a private residence, and the grower must take reasonable measures to restrict persons under age 21 years old from accessing the plants (i.e, restricting the cannabis from public view, utilizing a lock or security system, etc.).

New York Rules for Growing Cannabis at home

The new rules provide more options for patients and represent another step in expanding the state’s growing cannabis market, which is predicted to ultimately generate billions of dollars and create opportunities for all New Yorkers, particularly those from historically marginalized communities.

Along with rules for home cultivation, the state issued a Medical Home Cultivation Guide, a Medical Cannabis Home Cultivation Fact Sheet and a set of  Frequently Asked Questions (FAQs) on the Personal Home Cultivation of Medical Cannabis Regulations., plus information on how to become a certified patient or a designated caregiver

New York regulators and lawmakers continue to move quickly issuing guidance, comprehensive regulations and proposed laws surrounding the cannabis industry. The Harris Beach team is monitoring the legal landscape to answer the growing number of questions raised by our clients. We look forward to providing insights and guidance to help clients navigate this rapidly evolving area of law.

For more information, please contact Meaghan T. Feenan, who advises organizations of all structures on developments within the Marijuana Regulation and Taxation Act (MRTA), including cultivators and processors, retailers, and distributors. She’s a frequent speaker on Cannabis topics and regularly publishes articles about the licensing process and legislative updates.

State Cannabis Advisory Committee releases summary of Kentuckians’ feedback on medical use – LINK nky

Is it time for medical cannabis in the Commonwealth?

Kentucky Gov. Andy Beshear seems to think so. And so do many Kentuckians.

Beshear released a summary of feedback obtained by his Team Kentucky Medical Cannabis Advisory Committee, a group created to travel the state and listen to Kentuckians’ views on medical cannabis.

Rep. Rachel Roberts (D-Newport) introduced legislation in February that would have allowed for recreational and medicinal marijuana. Ultimately, the state legislature did not pass the legislation.

“Kentuckians agree that it is past time for the Commonwealth to take action on legalizing medical cannabis,” Beshear said.

The summary from the committee included these key findings, as presented by the governor’s office:

  • Kentuckians of all ages are suffering from chronic conditions. Medical providers are prescribing opioids and painkillers that are not providing relief, and Kentuckians are fearful of their addictive properties. Research indicates individuals cannot overdose from cannabis.
  • Kentuckians are leaving the state to access medical cannabis in states where it is legal. They want to be able to return to the commonwealth without breaking the law.
  • Kentucky military veterans explained that PTSD was significantly eased by the use of cannabis.

“Polling suggests 90% of Kentucky adults support legalizing medical cannabis. Our team traveled the state to talk directly to Kentuckians, and they found our people do indeed overwhelmingly support it,” Beshear said. “I appreciate the work of those who participated, and I am taking this information into consideration as I analyze what steps I can take to legalize medical cannabis for those suffering from chronic, debilitating medical conditions.”

Kerry Harvey, co-chair of the committee and secretary of the Justice and Public Safety Cabinet, said the committee did not hear any opposition to medical cannabis legislation at its town hall meetings.

“Everyone who spoke supported legalizing medical cannabis in Kentucky,” Harvey said. “We heard from many Kentuckians that use cannabis for its beneficial medical effects but can only do so by breaking the law as it now exists. Many of these Kentuckians must leave the commonwealth to legally obtain medical cannabis in one of the 38 states where it is legal.”

Many attendees of the town hall told the committee that medical cannabis use helped relieve them from the chronic symptoms they live with. Some attendees told the committee that cannabis use helped them engage in day to day activities.

Some attendees felt that medical cannabis provided effective treatments for their chronic symptoms while other treatments such as opioids did not.

“Our nation is dealing with a critical crisis from the overuse of addictive opioids. The people we heard from are looking for pain relief that allows them to live useful, productive lives,” said Ray Perry, co-chair of the committee and secretary of the Public Protection Cabinet. 

Military veterans who attended the town halls spoke on the benefits they experienced from use of cannabis in reducing PTSD symptoms.

The state’s medical cannabis website allowed Kentuckians to submit their opinions online. The website received 3,539 comments, 98.64% of which expressed support for legalizing medical cannabis in Kentucky.

Global Cannabis Stocks Index Melts Down in September – New Cannabis Ventures

After breaking a long negative streak in July of 17 straight months down and then a rally of 4.3%, the Global Cannabis Stock Index fell 1.3% in August. In September, it posted a new all-time closing low on 9/30 at 11.26 and ended the month down 25.9%:

After a 26% decline in 2021, the index, which posted an all-time closing low on August 23rd at  14.36 and 26 names, is down 65.7% thus far in 2022:

The index is down substantially from the close on 6/30, falling 23.7% in Q3:

The strongest 4 names in September all fell:

Innovative Industrial Properties fell the least, but it lost 19.5% during Q3 and is down 66.3% year-to-date. Chicago Atlantic, and IPO from late 2021, fell just 4.3% during Q3 and is down just 13.5% year-to-date. Cronos Group was unchanged during the quarter and is down 28.1% year-to-date. Turning Point Brands, a hybrid business, dropped 21.7% during the quarter and is down 43.8% so far in 2022.

The 4 weakest names in September all declined by over 40%:

Leafly was the worst stock for the second straight month. It has dropped 93.2% since the end of 2021, when it was trading as a SPAC. In Q3, it dropped 84.9%. Ayr Wellness has lost 84.4% in 2022, and it fell 52.2% in Q3. Hydrofarm, down 93.2% year-to-date, like Leafly, dropped 44.3% during the quarter. Trulieve has declined 67.3% so far in 2022, and it fell 43.9% during Q3.

The index will expand to 28 members in Q4. Leaving the index are two ancillary names, CEA Industries (NASDAQ: CEAD) and Leafly. Both failed to have the minimum $800K of average daily traded value. Leafly was also below the minimum price of $1 as of 9/23, the date we used to rebalance the index, though the 10-day moving average was above it at the time. Note that we changed a rule slightly. Companies that are dual-listed in Canada were required to have average daily U.S. trading value in excess of $500K, but this is now $400K. Joining the index  for the first time are BYND Cannasoft Enterprises (NASDAQ: BCAN) (CSE: BYND) and recent IPO Hempacco (NASDAQ: HPCO). Returning are Columbia Care (OTC: CCHWF) (CSE: CCHW) (NEO: CCHW) and SND Inc. (NASDAQ: SNDL).

We will summarize the index performance again in a month. You can learn more about the index members and the qualifications for inclusion by visiting the Global Cannabis Stock Index. Be sure to bookmark the page to stay current on cannabis stock price movements within the day or from day-to-day. A more complete analysis of the index is available at

New Cannabis Ventures maintains seven proprietary indices designed to help investors monitor the publicly-traded cannabis stocks, including the Global Cannabis Stock Index as well as the Canadian Cannabis LP Index and its three sub-indices. The sixth index, the American Cannabis Operator Index, was launched at the end of October 2018 and tracks the leading cultivators, processors and retailers of cannabis in the United States. More recently, we introduced the Ancillary Cannabis Index at the end of March 2021, reflecting the increasing number of publicly-traded companies providing goods or services to cannabis operators.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter

Carson City Planning Commission approves permit for new cannabis store – Carson Now

The Carson City Planning Commission approved a request for a Special Use Permit for a new retail marijuana store at the Sept. 28 meeting.

The store will be approximately 4,000 square feet in size near the intersection of Hwy 50 W and S. Carson Street.

The permit of the project will not be effective until Oct. 1 since that is the date applied for the Ordinance 2022-19. The ordinance allows for an increase in the allowable number of marijuana retail stores to 4 and permits drive-through services.

The proposed structure will also be constructed to accommodate other permitted uses within the General Commercial zoning district, such as a restaurant.

Qualcan, LLC, the applicant of the request, proposed a structure size that was approved for 7,978 square feet. The marijuana retail store will be 3,978 square feet and the vacant space will take up 3,724 square feet, according to the report.

The drive through on the premises was also approved, with the condition of a visible and operable security surveillance system. The hours of operation are also limited to being open from 8:00 a.m. to 10:00 p.m., seven days per week.

Since the retail store is near a residential area, public notices were mailed to 46 property owners within 1500 feet of the subject site on Sept. 15. The staff received six written public comments about concerns from the nearby owners, most of them surrounding hours of operation worries, traffic and parking concerns with the drive through, billboard concerns and privacy wall conditions.

According to the late material item added to the report, seven provisions were added to the permit before approval, including increased signage, increased security, a privacy wall, improved billboard conditions and city and sewage requirements.

The Planning Commission went forward and authorized the permit to be granted to Qualcan, LLC.

Gov. Beshear’s advisory committee reports: Kentuckians want medical cannabis legalized –

Legal Cannabis Offers "dry January" Alternative

Share This Story

FRANKFORT, Ky. – Gov. Andy Beshear says polling suggests 90% of adults in Kentucky support legalizing medical cannabis.

The governor’s Team Kentucky Medical Cannabis Advisory Committee traveled the state to hear views on the topic after the state legislature failed to pass legislation earlier this year.

According to a release by Beshear’s office, the governor said the summary from the committee included these key findings:

  • Kentuckians of all ages are suffering from chronic conditions. Medical providers are prescribing opioids and painkillers that are not providing relief, and Kentuckians are fearful of their addictive properties. Research indicates individuals cannot overdose from cannabis.
  • Kentuckians are leaving the state to access medical cannabis in states where it is legal. They want to be able to return to Kentucky without breaking the law.
  • Kentucky military veterans explained that PTSD was significantly eased by the use of cannabis.

In addition to town hall meetings, the state’s medical cannabis website allowed Kentuckians to submit their opinions online. The website received 3,539 comments, 98.64% of which expressed support for legalizing medical cannabis in Kentucky.

“I appreciate the work of those who participated, and I am taking this information into consideration as I analyze what steps I can take to legalize medical cannabis for those suffering from chronic, debilitating medical conditions,” said Beshear.

FDA Hires Cannabis Policy Advisor – LA Weekly

The Food and Drug Administration (FDA) has tapped Norman Birenbaum to be its first senior policy advisor on cannabis regulatory matters. 

The move means a variety of things for cannabis going forward. Whether it’s just pointing to the day as another where it became that much more wildly evident how normalized cannabis is becoming, or as clear evidence of the feds attempting to get their ducks in a row for what is to come. 

Birenbaum spent the last few years helping New York transition to the era of legal cannabis. He also made a wildly graceful exit presuming a future crackdown on the large amount of sellers currently operating in the gray market, be it from pop-up tables in central park or modified school buses. While in jest, the light-handed enforcement situation is exactly what regulators should be doing while they figure it out. This would bode well for a federal transition to legalization under the guidance of someone like Birenbaum. 

Birenbaum has actively taken a role in pushing wider regulatory progress since taking on the New York gig, where he helped then-governor Andrew Cuomo usher in the eras of legal cannabis in what was once where the enforcement of cannabis laws was most oppressive. Much of the time over the years that enforcement was targeted at black and brown youth as the research showed time and time again. 

Before the move to New York, Birenbaum helped rework Rhode Island’s medical cannabis program. Birenbaum’s work now transcends the state level. He was the inaugural president of The Cannabis Regulators Association. 

“The Cannabis Regulators Association will provide a much-needed forum for regulators to engage with each other, to identify and develop best practices, create model policies that safeguard public health and safety, and promote regulatory certainty for industry participants,” Birenbaum said at the time of the CRA’s launch. 

Coming from that kind of collaborative headspace as a regulator is going to be key. Half the problems in the game started with someone that was sure they were right and the rest of us are likely still paying for it. 

NORML Political Director Morgan Fox couldn’t speak to Birenbaum’s work in NY, but he was certainly happy to see the FDA making policy moves. 

“Given the agency’s relatively ineffective approach to this issue over the years, it is good to see them being more proactive and bringing on people with actual cannabis experience,” Fox told L.A. Weekly. “The FDA’s work related to cannabis is likely going to increase and become more complicated in the not-too-distant future, and it should be preparing for this now by continuing to bring on additional staff with a wide array of expertise in the space.”

The National Cannabis Industry Association (NCIA) also was happy to see someone with a bit more cannabis experience getting in the mix at the FDA.

Aaron Smith, NCIA’s founder, told L.A. Weekly, “We’re hopeful that Mr. Birenbaum’s background in cannabis regulations will bring to the FDA the experience and understanding of the nuances they will need to effectively regulate the vastly diverse array of cannabinoid products, including CBD products an increasing number of Americans are relying on for pain relief and other benefits.”

The US Cannabis Council (USCC) also is backing the move. It’s one of the newer faces in cannabis policy given NORML and MPP’s decades-long histories of pushing reform in the nation’s capital. But MPP (Marijuana Policy Project) did join over 60 other organizations in the group. Some of them have been around longer than others, but the collective lobbying power is undeniable. 

“We’re pleased that the Biden administration has signaled its growing interest in good-faith engagement on cannabis issues by creating a new adviser position within the FDA dedicated to cannabis research and regulation,” Khadijah Tribble, USCC CEO. “Mr. Birenbaum’s vast experience managing multiple states’ medical cannabis efforts will surely inform how he approaches the challenges and opportunities ahead for our growing industry. The USCC is ready and eager to work with Mr. Birenbaum on all aspects of cannabis reform.”

Advertising disclosure: We may receive compensation for some of the links in our stories. Thank you for supporting LA Weekly and our advertisers.